SecBot SecBot
SECBOTREPLAY Home › Report › HRTX

HRTX · Asset sale to CorMedix

HERON THERAPEUTICS, INC. /DE/ · DEFA14A filed Nov 9, 2026 at 08:20 ET

At the news

NEUTRALIMPACT 6/10

DEFA14A filed Nov 9, 2026 at 08:20 ET

Heron Therapeutics (HRTX) entered into a definitive Asset Purchase Agreement to sell substantially all of its assets to CorMedix Inc. for $145M in cash plus 14.6M CorMedix shares, contingent royalties on CINVANTI/SUSTOL sales above $25M in 2027-2029, and earn-out payments on ZYNRELEF sales in 2028. The deal requires HRTX stockholder approval, HSR clearance, and Nasdaq listing of the stock consideration. Supporting stockholders owning ~22% of HRTX shares have agreed to vote in favor. HRTX will retain its NOLs and the CorMedix shares received, and intends to remain publicly traded while evaluating strategic alternatives for the proceeds.

  • Heron Therapeutics agreed to sell substantially all assets to CorMedix Inc.
  • Total cash consideration is $145.0M, subject to working capital and closing cash adjustments
  • Stock consideration: 14,583,333 shares of CorMedix common stock
  • Contingent royalties: 5% of annual net sales of CINVANTI/SUSTOL above $25M in 2027, 2028, 2029

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access